Dominant-negative PD1-armored CART cells induce remission in refractory diffuse large B-cell lymphoma (DLBCL) patients.

Tong Chen,Yan Yuan,Liansheng Huang,Chengfei Pu,Tianling Ding,Xibin Xiao,Zhiyuan Cao,Ting Wu,Luying Ding,He Sun,Zhao Wu,Lei Xiao,Xiaohong Zhang

Dominant-negative PD1-armored CART cells induce remission in refractory diffuse large B-cell lymphoma (DLBCL) patients.

2019

Tong Chen
Yan Yuan
Liansheng Huang
Chengfei Pu
Tianling Ding
Xibin Xiao
Zhiyuan Cao
Ting Wu
Luying Ding
He Sun
Zhao Wu
Lei Xiao
Xiaohong Zhang

e19028Background: The chimeric antigen receptor (CAR) T cell treatment has been demonstrated as an effective therapy to relapse/refractory B cell malignancy. However, tumor microenvironment influen...

Keywords:

Refractory
Tumor microenvironment
Pathology
Refractory Diffuse Large B-Cell Lymphoma
Malignancy
Chimeric antigen receptor
T cell
B cell
Medicine
Cart
dominant negative
b cell malignancy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations